Thursday
11.21.2019
6:00 AM
Login form
Search
Calendar
«  August 2014  »
SuMoTuWeThFrSa
     12
3456789
10111213141516
17181920212223
24252627282930
31
Entries archive

My site

Main » 2014 » August » 23

COLOMBES, France - Friday, August 22nd 2014 [ME NewsWire]

(BUSINESS WIRE)-- Oberthur Technologies, a world leader in digital security solutions for the mobility space, today announced that it will present its second quarter 2014 financial results to investors on Friday August 29th, 2014.

Didier Lamouche (CEO) and Anne-France Laclide (CFO) will be presenting these financial results and taking questions the same day at 4pm CEST (3pm BST/ 10am EDT).

In order to access the conference call dial-in details, you need to register with Investor Relations: investors@oberthur.com.

If you have already registered, details are available on our website: http://investors.oberthur.com

ABOUT OBERTHUR TECHNOLOGIES

OT is a world leader in digital security solutions for the mobility space. OT has always been at the heart of mobility, from the first smart cards to the latest contactless payment technologies which equip millions of smartphones. Present in th ... Read more »

Views: 74 | Added by: uaeonlinenews | Date: 08.23.2014

ME NewsWire/Business Wire

SUMMIT, N.J. - Thursday, August 21st 2014

Celgene Corporation (NASDAQ:CELG) today announced that results of a study evaluating the combination of REVLIMID® (lenalidomide) with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate and prednisone (R-CHOP) in untreated diffuse large b-cell lymphoma (DLBCL) were published online ahead of print in the Journal of Clinical Oncology.

In a phase II, open label, single arm study, by Dr. Grzegorz Nowakowski of the Mayo Clinic, 64 patients with newly diagnosed, untreated, stage II-IV CD20 positive DLBCL received 25 mg of lenalidomide on days 1-10 with standard dose R-CHOP every 21 days for six cycles. All patients received pegfilgrastim on day two of each cycle and aspirin prophylaxis throughout. The primary endpoint was event-free survival (EFS) with secondary endpoints of progression free survival (PFS) and overall survival (OS). A one-stage binomial design was used t ... Read more »

Views: 101 | Added by: uaeonlinenews | Date: 08.23.2014

Clinical Study in the Journal of Clinical Oncology Reports Patients with Diffuse Large B-Cell Lymphoma Receiving Oral REVLIMID with Standard R-CHOP Achieved 98% Overall Response Rate and 80% Complete Response Rate

Views: 85 | Added by: uaeonlinenews | Date: 08.23.2014

CARY, N.C. - Thursday, August 21st 2014 [ME NewsWire]

(BUSINESS WIRE)-- Project Data Sphere, LLC has appointed Kald Abdallah, MD, PhD as Chief Project Data Sphere Officer, charging him with continuing the rapid development of www.ProjectDataSphere.org which is providing broad access to cancer research databases, enabling unprecedented research collaboration to solve complex scientific problems.

“Dr. Abdallah has a track record of helping align data contributors with the innovative approach to cancer research that the Project Data Sphere initiative represents and that cancer patients deserve,” said Christopher A. Viehbacher, President and CEO of Project Data Sphere, LLC and also Chair of the CEO Roundtable on Cancer and Chief Executive Officer of Sanofi.

Project Data Sphere, LLC, is an independent not-for-profit initiative of the CEO Roundtable on Cancer’s Life Sciences Consortium. The CEO Roundtable on Cancer was established in 2001 with the ... Read more »

Views: 110 | Added by: africa-live | Date: 08.23.2014 | Comments (0)